Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer, building on years of research at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute. Neon’s lead program, NEO-PTC-01, is a personal neoantigen-based T cell therapy that will be tested first in melanoma and ovarian cancer.